Epithalon / Epitalon Information & Coordination for Licensed U.S. Clinics
Epithalon, also commonly spelled Epitalon, is a short peptide composed of four amino acids: alanine, glutamic acid, aspartic acid, and glycine.
FDA’s current compounding materials use the name Epitalon and evaluate Epitalon free base and Epitalon acetate separately.
Phoenix Meds Inc. supports licensed U.S. healthcare organizations with clinic verification, documentation organization, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
Phoenix Meds is not a pharmacy, medical practice, manufacturer, prescriber, wholesaler, distributor, or dispensing entity.
What Licensed Clinics Should Know About Epitalon
Epitalon has been studied in preclinical and limited human literature, but those studies do not establish an FDA-approved clinical use.
FDA’s July 2026 section 503A evaluation considered Epitalon free base and Epitalon acetate in connection with a nominated use for insomnia. FDA concluded that the evaluation criteria weighed against placing either substance on the 503A Bulks List.
FDA also notes that the common name “Epitalon” has been used inconsistently for different salts and related substances. For that reason, substance identity and formulation details are important when reviewing a specific preparation.
Clinics should distinguish the peptide name from the exact chemical form, route, labeling, pharmacy information, and supporting documentation associated with the preparation under review.
Current FDA and Compounding Status
In July 2026, FDA presented Epitalon free base and Epitalon acetate to the Pharmacy Compounding Advisory Committee as part of its evaluation for possible inclusion on the section 503A Bulks List.
FDA’s briefing materials proposed that neither Epitalon free base nor Epitalon acetate be included on the 503A Bulks List.
That proposal should not be described as FDA approval, a product-specific ban, or a determination that applies automatically to every preparation using the Epitalon name.
FDA also states that compounded drugs containing Epitalon may present immunogenicity risks for certain routes of administration because of potential aggregation and peptide-related impurities. FDA has further noted that it lacks sufficient safety information to determine whether Epitalon would cause harm when administered to humans.
Compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality in the same manner as FDA-approved drug products.
Why Substance Identity Matters
FDA has specifically noted that the name “Epitalon” may refer to different salts or related substances. For professional review, clinics may need to consider:
- whether the preparation contains Epitalon free base, Epitalon acetate, or another identified form;
- formulation details;
- route of administration;
- product labeling;
- pharmacy information;
- storage information supplied with the preparation; and
- supporting documentation associated with the specific preparation.
The name alone does not establish FDA approval, compounding eligibility, product quality, safety, effectiveness, or clinical suitability.
Phoenix Meds can help organize available documentation and publicly available regulatory information so questions about the preparation can be directed to the appropriately licensed parties.
How Phoenix Meds Supports Licensed Clinics
Phoenix Meds helps licensed U.S. healthcare organizations manage the administrative work involved in clinic-pharmacy communication.
For Epitalon-related professional inquiries, our support may include clinic credential verification, organization of available formulation and pharmacy documentation, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
We can also help organize documentation follow-up so clinic teams have a clearer administrative record before questions move to the professionals responsible for clinical and pharmaceutical decisions.
Phoenix Meds does not determine whether a particular preparation may be compounded, prescribe treatment, certify pharmacy compliance, or determine clinical appropriateness.
Safety and Documentation Considerations
Because FDA has identified limited human safety information for Epitalon, clinics should avoid assuming that investigational or preclinical findings establish safety or effectiveness in clinical use.
Relevant information may include substance identity, formulation details, labeling, route, storage information, dispensing-pharmacy information, and supporting records supplied with the preparation.
Phoenix Meds may help organize those materials as part of its administrative role.
We do not independently test or certify purity, potency, sterility, stability, authenticity, safety, effectiveness, or regulatory compliance.
Epitalon Administrative Coordination for Licensed Clinics
Clinic Verification
Documentation Review
Licensed Parties
Frequently Asked Questions
Is Epitalon FDA-approved?
No FDA-approved drug product containing Epitalon free base or Epitalon acetate was identified in FDA’s current review materials. FDA states that neither form is a component of an FDA-approved drug.
What is Epitalon’s current 503A status?
FDA evaluated Epitalon free base and Epitalon acetate during its July 2026 Pharmacy Compounding Advisory Committee process.
FDA’s briefing materials proposed that neither form be included on the section 503A Bulks List.
That proposal is part of FDA’s evaluation process and should not be described as FDA approval or as a blanket product-specific ban.
How has FDA evaluated Epitalon under section 503A?
FDA presented Epitalon free base and Epitalon acetate to the Pharmacy Compounding Advisory Committee in July 2026 as part of its evaluation for possible inclusion on the 503A Bulks List.
FDA’s briefing materials proposed that neither substance be included on the list.
That proposal is part of FDA’s regulatory evaluation process and should not be described as FDA approval, a blanket product-specific ban, or a determination that every preparation marketed under the Epitalon name has the same regulatory status.
Has FDA identified safety concerns with Epitalon?
FDA states that compounded drugs containing Epitalon may pose immunogenicity risks for certain routes because of potential aggregation and peptide-related impurities.
FDA also states that it lacks sufficient safety information to determine whether Epitalon would cause harm in humans.
Does Phoenix Meds determine whether Epitalon can be compounded?
No. Product-specific compounding and dispensing determinations remain with the appropriately licensed pharmacy and other responsible professionals.
Does Phoenix Meds test or certify Epitalon preparations?
No.
Phoenix Meds does not independently test or certify purity, potency, sterility, stability, authenticity, safety, effectiveness, or clinical suitability.
What can Phoenix Meds help licensed clinics with?
Phoenix Meds can support clinic credential verification, documentation organization, access to publicly available regulatory information, and administrative communication relating to clinic-pharmacy coordination.
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, wholesaler, distributor, prescriber, or dispensing entity.
Information on this page is intended for professional informational purposes. It is not medical advice, a prescribing recommendation, FDA approval, or a determination that a particular Epitalon preparation is available, eligible for compounding, safe, effective, or clinically appropriate.
Regulatory Resources
- FDA — Briefing Document for Epitalon-Related Bulk Drug Substances
- FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting
- FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- FDA — Bulk Drug Substances Used in Compounding Under Section 503A
- FDA — Compounding and FDA: Questions and Answers